Izokibep Improves Multiple PsA Symptoms in Phase 2 Study

Greater percentages of patients treated with one of two doses of the novel IL-17 blocker achieved an ACR 50 response vs placebo.
Medscape Medical News

source https://www.medscape.com/viewarticle/975169?src=rss